Source comparison
Tesamorelin Per Day Daily Dose: Comparison by Research Context
Visceral Fat Reduction Trials 2mg subcutaneous +80–120 ng/mL from baseline Evening (within 2 hours of sleep) 12–16 weeks for VAT reduction ≥10% Gold standard dose. Supported by Phase 3 data and FDA review. Doses below 1.5mg show inconsistent IGF-1 response; do
This comparison does not assign a generated winner or score.
- Visceral Fat Reduction Trials
- 2mg subcutaneous
- +80–120 ng/mL from baseline
- Evening (within 2 hours of sleep)
- 12–16 weeks for VAT reduction ≥10%
- Gold standard dose. Supported by Phase 3 data and FDA review. Doses below 1.5mg show inconsistent IGF-1 response; doses above 2.5mg increase glucose intolerance without proportional fat loss benefit.
- Lipodystrophy Protocols (HIV-Associated)
- +100–130 ng/mL from baseline
- Evening preferred, morning acceptable
- 8–12 weeks for trunk fat redistribution
- Consistent with FDA-approved indication. Evening dosing aligns with endogenous GH pulsatility and produces 15–20% higher mean IGF-1 than morning administration at identical dose.
- Cognitive Function Studies (Off-Label)
- 1–2mg subcutaneous
- +60–100 ng/mL from baseline
- Evening
- 8–16 weeks for cognitive biomarker changes
- Lower doses (1–1.5mg) sometimes used to minimize glucose effects while preserving IGF-1 neuroprotective signaling. Evidence for cognitive benefit remains preliminary. Dosing not standardized.
- Muscle Preservation During Caloric Deficit
- +80–110 ng/mL from baseline
- 6–10 weeks for lean mass preservation vs control
- Dose matches VAT reduction protocols. IGF-1 elevation counters catabolic signaling during energy restriction, but benefit requires protein intake ≥1.6g/kg/day. Tesamorelin alone doesn't prevent muscle loss in hypocaloric states.